The CooperCOO -0.05%84 Forward PE Ratio is 14.50 as of Jul. 07, 2026. GuruFocus rates COO with a GF Score™ of 84/100 and a GF Value™ of $101.07 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 392 Medical Devices & Instruments companies, The Cooper ranks better than 69.13% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
The Cooper Forward PE Ratio Related Terms
The Cooper Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for The Cooper's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper Forward PE Ratio Chart
The Cooper Annual Data
Trend
2016-10
2017-10
2018-10
2019-10
2020-10
2021-10
2022-10
2023-10
2024-10
2025-10
Forward PE Ratio
18.18
22.57
20.53
21.23
26.39
29.24
19.84
21.41
26.45
16.70
The Cooper Quarterly Data
2016-01
2016-04
2016-07
2016-10
2017-01
2017-04
2017-07
2017-10
2018-01
2018-04
2018-07
2018-10
2019-01
2019-04
2019-07
2019-10
2020-01
2020-04
2020-07
2020-10
2021-01
2021-04
2021-07
2021-10
2022-01
2022-04
2022-07
2022-10
2023-01
2023-04
2023-07
2023-10
2024-01
2024-04
2024-07
2024-10
2025-01
2025-04
2025-07
2025-10
2026-01
2026-04
Forward PE Ratio
14.58
16.29
19.23
18.18
19.84
21.88
23.09
22.57
21.28
19.57
20.04
20.53
21.83
24.69
26.11
21.23
27.03
22.88
23.26
26.39
29.59
33.33
29.59
29.24
27.62
25.84
22.27
19.84
25.58
30.58
27.55
21.41
26.95
25.25
23.42
26.45
24.58
20.29
16.88
16.70
18.02
13.95
COO vs SOLV, ALGN, BAX: Forward PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where The Cooper's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
The Cooper (COO) has a Forward PE Ratio of 14.50 as of Jul. 07, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on The Cooper and its competitors. According to the industry distribution chart, The Cooper ranks #121 out of 392 companies in the Medical Devices & Instruments industry, placing it in the top 30.9%.
Is The Cooper's Forward PE Ratio too high?
The Cooper's current Forward PE Ratio is 14.50. The Medical Devices & Instruments industry median Forward PE Ratio is 19.23. The Cooper's value of 14.50 is 24.6% below this industry median. Based on the distribution chart, The Cooper ranks #121 out of 392 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Forward PE Ratio compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #121 out of 392 companies for Forward PE Ratio. This puts The Cooper in the upper half of its industry. The industry median Forward PE Ratio is 19.23. The Cooper's value of 14.50 is 24.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.23, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current Forward PE Ratio of 14.50 is 24.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current Forward PE Ratio is 14.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.07, compared to a current price of $72.57 — trading 28.2% below its estimated fair value. The current Forward PE Ratio is 14.50 and 24.6% below the Medical Devices & Instruments industry median of 19.23. The Cooper's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For The Cooper (COO), the current Forward PE Ratio is 14.50 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $72.57 is trading 28.2% below its estimated GF Value™ of $101.07.
GuruFocus considers The Cooper to be Modestly Undervalued.
Key valuation signals for COO:
Forward PE Ratio: 14.50
GF Value™: $101.07 vs. price of $72.57 (28.2% below fair value)
Industry Position: 24.6% below the Medical Devices & Instruments median (#121 of 392)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
84GF Score
Get the complete analysis for COO
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 